The first immune checkpoint inhibitor, ipilimumab, was approved by the FDA for the treatment of advanced melanoma in 2011. Since then, seven more (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, dostarlimab, and cemiplimab) have become available for the treatment of around 17 different types of cancer (as of December 2021). It was estimated that in 2018, over 40% of cancer patients in the US were eligible for treatment with immune checkpoint inhibitors and this proportion is likely to have increased since that time due to the rapid expansion of indications approved for these agents. ...
Advertisement
A study examined the effectiveness of adding pyrotinib, a new tyrosine kinase inhibitor (TKI).
Triple-negative breast cancer tends to have relatively poor long-term outcomes compared to other subtypes of breast cancer.
Patients with head and neck cancers may derive benefit from receiving oncology nurse navigation.
A study identified self-reported gaps from healthcare providers associated with providing treatment-related support.
The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.
“CTCs contribute to the metastatic cascade and represent an independent survival predictor in breast cancer."
Advertisement
Advertisement
Advertisement
Our Authors
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Owner of beyond Oncology Education, LLC, and Editor In Chief of Cancer Nursing Today
Joni L. Watson, DNP, MBA, RN, OCN®Oncology nurse and writer
Kate B. Hubbard, MSN, RN, OCN®, NPD-BCOncology nurse educator with over 15 years of oncology nursing experience
Stephanie DeMeyer, MAIndependent consultant helping organizations achieve their diversity, equity, and inclusion goals
